NewAmsterdam Pharma Company N.V. (NAMS) Net Income by Year
NewAmsterdam Pharma Company N.V. reported a net loss of $203.8M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $259.5M net loss. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters NewAmsterdam Pharma Company N.V. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
NAMS Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
NAMS Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More NewAmsterdam Pharma Company N.V. financials
Frequently Asked Questions
What was NewAmsterdam Pharma Company N.V.'s net income in fiscal year 2025?
NewAmsterdam Pharma Company N.V. reported a net loss of $203.8M in fiscal year 2025.
How fast is NewAmsterdam Pharma Company N.V.'s net income growing?
NewAmsterdam Pharma Company N.V. (NAMS) reported a $241.6M net loss in fiscal year 2024 and a $203.8M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
What is NewAmsterdam Pharma Company N.V.'s net income over the last twelve months?
NewAmsterdam Pharma Company N.V. (NAMS) reported a $259.5M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has NewAmsterdam Pharma Company N.V.'s net income changed over the years?
Across the 5 fiscal years this page covers, NewAmsterdam Pharma Company N.V. (NAMS) net income went from -$41.8M in fiscal year 2021 to -$203.8M in fiscal year 2025.
What was NewAmsterdam Pharma Company N.V.'s net income in the most recent quarter?
NewAmsterdam Pharma Company N.V. (NAMS) reported -$64.1M in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what NewAmsterdam Pharma Company N.V. (NAMS) reported on that line in every period on record.